The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Melanoma dormancy: Predictors of relapse in resected early-stage cutaneous melanoma.
 
Ilias Christodoulou
No Relationships to Disclose
 
Cindy Sander
No Relationships to Disclose
 
Shuaichao Wang
No Relationships to Disclose
 
Hong Wang
No Relationships to Disclose
 
Sabrina Bruno
Stock and Other Ownership Interests - Moderna Therapeutics
 
Raphael Crum
No Relationships to Disclose
 
John Kirkwood
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Ankyra Therapeutics; AXIO Research; Boxer Capital; Bristol Myers Squibb; CytomX Therapeutics; DermTech; Engage Health Media; iOnctura; Iovance Biotherapeutics; IQVIA; Istari Oncology; Jazz Pharmaceuticals; Lumira Capital Investment Management; Lytix Biopharma; Magnolia Innovation; Merck; Mural Oncology; Natera; Novartis; OncoCyte; PATHAI; Pfizer; Piper Sandler; PyrOjas Corporation; Regeneron; Replimune; Scopus BioPharma; Takeda; Valar Labs; Zola Therapeutics
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Harbour BioMed (Inst); Immunocore (Inst); Immvira (Inst); Iovance Biotherapeutics (Inst); Lion Biotechnologies (Inst); Lytix Biopharma (Inst); Novartis (Inst); Takeda (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Ankyra Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Iovance Biotherapeutics; Regeneron